FTSE MIB
33.308,77 -366,38 (-1,09%) Dow Jones
39.150,33 +15,57 (+0,04%) Nasdaq
17.689,36 -32,23 (-0,18%) Nikkei 225
38.596,47 -36,55 (-0,09%) Petrolio
80,59 -0,70 (-0,86%) Bitcoin EUR
60.263,90 +270,48 (+0,45%)
Daxor Corporation (DXR)
| Chiusura precedente | 8,90 |
| Aperto | 8,85 |
| Denaro | 0,00 x 0 |
| Domanda | 0,00 x 0 |
| Min-Max giorno | 8,85 - 9,11 |
| Intervallo di 52 settimane | 7,11 - 10,15 |
| Volume | |
| Media Volume | 2.109 |
| Capitalizzazione | 43,786M |
| Beta (mensile su 5 anni) | -0,55 |
| Rapporto PE (ttm) | 65,07 |
| EPS (ttm) | 0,14 |
| Prossima data utili | 25 mar 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | 05 gen 2018 |
| Stima target 1A | 23,25 |
GlobeNewswireExpert Panelists Advocate Use of Daxor’s Technology to Optimize Treatment at Heart Failure Society of America Annual Scientific Meeting
Leading Clinicians Highlight Significant Outcome Improvements with Daxor’s Blood Volume Analysis Innovative Technology Oak Ridge, TN, Oct. 13, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces that experts recommend the use of blood volume analysis (BVA) to guide optimal treatment in heart failure patient at two Scientific Sessions held during the Heart Failure Society of America Annual Scientific Meeting on Octobe
- GlobeNewswire
New Data from Banner University Medicine Demonstrating Effectiveness of BVA-100® Use in Ambulatory Heart Failure Patients Presented at Heart Failure Society of America Annual Scientific Meeting
Blood Volume Analysis (BVA) in 83-Patient Study Provided Highly Effective Guidance for Care of Heart Failure Patients Otherwise Unavailable Using Common Proxy Diagnostic Methods Oak Ridge, TN, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ: DXR), the global leader in blood volume measurement technology, today announces new data from Banner University Medicine Advanced Heart Failure Clinic in Phoenix, AZ validating the benefits of the Company’s BVA-100 diagnostic blood test for ambul
- GlobeNewswire
Daxor Corporation Awarded Support from the National Institutes of Health (NIH) Catalyze Preclinical Services Program
Support for Development of Daxor’s Non-Nuclear Tracer for Next Generation Blood Volume Analyzer Systems Aims to Deliver Gold Standard Accuracy with Increased Access, Ease of Use, and Frequency of Testing Oak Ridge, TN, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ: DXR), the global leader in blood volume measurement technology, today announces it has been accepted into the National Institutes of Health (NIH) Catalyze Preclinical Services Program. This program supports preclinical d
